STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Company - BMY STOCK NEWS

Welcome to our dedicated page for Bristol-Myers Squibb Company news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Company stock.

Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.

Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.

Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.

News

Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer

Rhea-AI Summary
Bristol Myers Squibb (BMY) has completed the acquisition of RayzeBio, Inc. for approximately $4.1 billion, with 86% of RayzeBio's shares tendered. The transaction is expected to close on February 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
News

U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or...

Rhea-AI Summary
Bristol Myers Squibb's KRAZATI (adagrasib) in combination with cetuximab receives priority review by the FDA for treating KRAS G12C-mutated colorectal cancer, with a target action date of June 21, 2024, based on positive results from the Phase 1/2 KRYSTAL-1 study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes

Rhea-AI Summary
Bristol Myers Squibb (BMY) announces a public offering of senior unsecured notes totaling $13 billion to fund acquisitions and general corporate purposes. The offering includes nine tranches of notes with varying interest rates and maturity dates. The company plans to use the proceeds for proposed acquisitions of Karuna Therapeutics, Inc. and RayzeBio, Inc., as well as for general corporate needs. The offering is not contingent on the completion of the acquisitions, but failure to acquire Karuna by a specified date will trigger mandatory redemption of certain notes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none
News

Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC

Rhea-AI Summary
Bristol Myers Squibb (BMY) received an unsolicited 'mini-tender' offer from Tutanota LLC to purchase up to 500,000 shares at $55 per share, significantly below market price. The offer is subject to conditions and may extend for 45-180 days. Shareholders are advised not to tender shares due to risks and potential delays.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none
-
News

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Rhea-AI Summary
Bristol Myers Squibb's Augtyro sNDA for NTRK-positive solid tumors accepted by the FDA with a target action date of June 15, 2024, based on positive results from TRIDENT-1 and CARE trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
-
News

VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence

Rhea-AI Summary
VantAI and Bristol Myers Squibb collaborate to discover molecular glues for therapeutic targets, with VantAI eligible to receive up to $674 million in milestone payments and royalties. The partnership combines VantAI's generative AI platform with Bristol Myers Squibb's expertise in targeted protein degradation to develop new small molecule therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
none
News

Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period

Rhea-AI Summary
Bristol Myers Squibb (BMY) and RayzeBio, Inc. (RYZB) announce the expiration of the waiting period under the HSR Act for BMY's tender offer to acquire RYZB for $62.50 per share in cash, totaling $4.1 billion. The transaction remains subject to the tender of a majority of RYZB's outstanding shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
-
News

Healthpeak Properties Reports Fourth Quarter and Year Ended 2023 Results

Rhea-AI Summary
Healthpeak Properties, Inc. (NYSE: PEAK) announced fourth-quarter and full-year 2023 financial results, including net income, Nareit FFO, FFO as Adjusted, AFFO, and Total Same-Store Portfolio Cash NOI growth. The company also highlighted lease executions, lab developments, joint ventures, net debt, and 2023 sustainability recognitions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
none
-
News

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

Rhea-AI Summary
Bristol Myers Squibb (BMY) announced two regulatory acceptances for applications for neoadjuvant Opdivo with chemotherapy followed by surgery and adjuvant Opdivo for the perioperative treatment of resectable stage IIA to IIIB non-small cell lung cancer. The U.S. FDA accepted the supplemental Biologics Application (sBLA) and assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 8, 2024. The EMA also validated the type II variation application. The CheckMate -77T trial showed statistically significant improvements in event-free survival, pathologic complete response, and major pathologic response, with a consistent safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
none
News

Bristol Myers Squibb Named One of America’s Most JUST Companies by JUST Capital and CNBC

Rhea-AI Summary
Bristol Myers Squibb Company has achieved a top 10 ranking in the Pharmaceutical and Biotech Sector, reflecting the company's strong standing in issues that are important to Americans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
none

FAQ

What is Bristol-Myers Squibb's core business?

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs for various therapeutic areas, including cardiovascular, cancer, and immune disorders.

Where is Bristol-Myers Squibb headquartered?

Bristol-Myers Squibb is headquartered in New York City, USA.

What was Bristol-Myers Squibb's revenue for fiscal 2022?

Bristol-Myers Squibb reported a total revenue of $46.2 billion for fiscal 2022.

What is a significant focus area for Bristol-Myers Squibb?

A significant focus area for Bristol-Myers Squibb is immuno-oncology, where it is a leader in drug development.

How much of Bristol-Myers Squibb's total sales come from the U.S. market?

Approximately 70% of Bristol-Myers Squibb's total sales are derived from the U.S. market.

What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?

On May 22, 2024, Bristol-Myers Squibb joined NeoPhore Limited's Series B extension round to explore novel biology associated with the DNA mismatch repair pathway in cancer.

What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?

The collaboration with I-Mab focuses on evaluating the combination of givastomig with BMS's nivolumab and chemotherapy for advanced Claudin 18.2-positive gastric and esophageal cancers.

What is SpliceCore®?

SpliceCore® is Envisagenics' cloud-based AI drug discovery platform that integrates machine learning algorithms to identify novel and disease-specific RNA splicing isoforms.

When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?

Bristol-Myers Squibb participated in Envisagenics' Series B fundraising round announced on June 5, 2024.

What is Bristol-Myers Squibb's mission?

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

Stock BMY logo
Bristol-Myers Squibb Company

NYSE:BMY

BMY Rankings

#122 Ranked by Market Cap
#501 Ranked by Dividends

BMY Stock Data

102.11B
2.03B
0.11%
79.27%
1.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PRINCETON